Anti-Bevacizumab (AVASTIN) Quantitative ELISA Assay Kit
The Anti-Bevacizumab (AVASTIN) Quantitative ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: 7.5 ng/mL
Standard Range: 0 – 160 ng/ml
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Name: Avastin
Controls Included
Assay Background
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab is an anti neoplastic agent and prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metastatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and endothelial cell proliferation.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the drug bevacizumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to bevacizumab antibodies captured by the drug bevacizumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of bevacizumab antibodies in the sample or standard. Results of samples can be determined directly using the standard curve.
